A food safety turnaround gaining traction amid heavy investment needs
- Neogen is focusing on Food Safety and Animal Safety while waiting to close its Genomics sale.
- First quarter core growth hit 8.1 percent, aided by favorable order timing.
- The company successfully validated its first Petrifilm product, reducing manufacturing transition risks.
- Regulatory agencies in Australia and New Zealand delayed their decision on the Genomics sale until December.
- The company is increasing research spending by 50 percent for fiscal 2027 to develop new products.
- Management successfully fixed previous material weaknesses in its internal financial controls.
Turnaround gaining momentum
Neogen is a turnaround story, and the new team is beginning to show results. The plan focuses on simplifying the company, fixing operations, and investing in higher-value food safety products. Recent quarters show strong execution, with first quarter core growth hitting 8.1 percent, though helped slightly by favorable timing. Management also removed a major cloud over the company by successfully fixing material weaknesses in its internal financial controls.
The most compelling part of the story is the renewed focus on organic growth and the critical Petrifilm manufacturing transition. The company recently achieved a major milestone by fully validating its first Petrifilm product. This materially reduces the risk of the complex manufacturing move that begins in November 2026. At the same time, Animal Safety has rebounded as the team fixed major supplier disruptions.
The weakest part is near-term profit margin pressure and regulatory delays. The company is increasing research and development investment by 50 percent for fiscal 2027 to fund its innovation plans, which limits profit growth in the short run. Significant margin expansion is pushed out to fiscal 2029. Additionally, the planned sale of the Genomics business is facing deeper regulatory reviews in Australia and New Zealand, with a final decision pushed to December 2026.
The bull case needs three things to happen together. The Genomics sale must clear regulatory hurdles, the massive Petrifilm manufacturing transition must continue smoothly across all remaining products, and new partnerships like the Hinalea hyperspectral imaging deal must produce actual sales. The bear case is simple. The required investments push out margin targets, and the manufacturing transition leaves no room for error.
Tests, consumables, and channel trust
Neogen makes money by selling testing products, safety products, and related services. Many products are used repeatedly by food plants, labs, veterinarians, livestock producers, and animal health customers. That repeat use matters because the company is not only selling machines or one-time projects. Management is now shifting toward selling complete solutions rather than individual products.
Food Safety is the main engine. Customers use Neogen products to test for pathogens, allergens, toxins, sanitation problems, and other risks in food and feed. Rules around food testing and brand risk support long-term demand, and core growth in this segment has been accelerating.
Animal Safety sells items such as rodent control, insect control, veterinary instruments, and biosecurity products. It also still includes Genomics until the Zoetis sale closes. This segment is more exposed to cyclical animal markets and supplier problems, though supply issues have recently stabilized and the segment returned to positive growth.
The balance sheet is a key part of the story. Neogen carries significant debt from its prior acquisitions. Management plans to use Genomics sale proceeds to repay debt and strengthen its financial position, provided regulators approve the deal by year-end.
What Neogen sells
Petrifilm and indicator testing
Petrifilm is a core Food Safety platform used for microbial testing. The successful validation of the first new product reduces risk for the upcoming manufacturing transition.
Pathogen detection
These products help food producers and labs detect harmful organisms. This line has helped drive recent Food Safety business growth.
Sample collection and culture media
These products support routine testing work in food plants and labs. They remain a core part of the daily testing workflow.
Natural toxins, allergens, and sanitation tests
These tests help customers check food, feed, and facilities for safety issues. Demand is tied to testing rules and customer quality programs.
Rodent, insect, and biosecurity products
These Animal Safety products help farms, facilities, and animal owners control pests and disease risks. The supply chain has stabilized after recent disruptions.
Veterinary instruments and disposables
Neogen sells tools and supplies used by vets and animal health customers. This product line faces cyclical demand in agricultural markets.
Genomics services
Genomics provides testing services for production and companion animals. Neogen has agreed to sell this business to Zoetis, making it a near-term deleveraging asset pending regulatory approval.
Food Safety drives the business
Segment mix relies on trailing revenue data from fiscal 2026. Food Safety represents roughly three quarters of the business, but Genomics remains inside reported segments until the pending Zoetis deal closes.
What could break the plan
Petrifilm transfer disruption
High impact · Medium oddsNeogen is bringing Petrifilm manufacturing in-house, with the transition starting in November 2026. While the first product was successfully validated, moving the remaining products over multiple quarters carries execution risk. If the transfer causes quality issues, backlogs, or lost customers, the bull case weakens fast.
Investment pressures margins
Medium impact · High oddsManagement increased research and development investment by 50 percent for fiscal 2027. The goal is to drive long-term organic growth, but this heavy spending pushes significant profit margin expansion out to fiscal 2029.
Genomics divestiture delays
High impact · Medium oddsThe planned sale of the Genomics business is facing extended regulatory scrutiny from agencies in Australia and New Zealand, with a decision expected in December 2026. If regulators block the deal or demand major remedies, Neogen would be left with a non-core asset and fewer funds to pay down debt.
Supply chain fragility
Medium impact · Medium oddsEarlier in 2026, Animal Safety suffered from severe third-party supplier quality and manufacturing problems. Management says they have resolved the majority of these issues, but supplier reliance remains an inherent risk.
In one breath
What does Neogen Corporation do?
Neogen sells food and animal safety products. Its Food Safety products help test food, feed, and facilities for contamination, while Animal Safety products serve vets, farms, livestock producers, and animal health channels.
Why is Neogen selling Genomics?
Management wants to simplify the company and focus on core Food Safety and Animal Safety products. Neogen agreed to sell Genomics to Zoetis and expects to use proceeds to reduce debt, though the deal is currently facing regulatory reviews.
What is Petrifilm, and why does it matter?
Petrifilm is a key Food Safety testing platform that came with the 3M Food Safety business. Neogen is bringing its manufacturing in-house and successfully validated its first product, aiming to speed up innovation with two new versions per year.
What is the biggest near-term risk for Neogen stock?
The clearest near-term risk is execution. Investors need to see the Petrifilm manufacturing move stay on schedule without hurting customers, and margins must hold up during a heavy investment phase.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- October 25, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Diagnostics & Research companies
Companies near Neogen Corporation in Finn's Diagnostics & Research industry ranking.

